APA (7th ed.) Citation

PU, O., F, R., P, A., P, K., M, G., A, R., . . . AD, K. (2026). Author Correction: Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial. Nature medicine, 32(6), 2319. https://doi.org/10.1038/s41591-026-04425-3

Chicago Style (17th ed.) Citation

PU, Ogbogu, et al. "Author Correction: Benralizumab Versus Placebo for Hypereosinophilic Syndrome: A Randomized, Placebo-controlled Phase 3 Trial." Nature Medicine 32, no. 6 (2026): 2319. https://doi.org/10.1038/s41591-026-04425-3.

MLA (9th ed.) Citation

PU, Ogbogu, et al. "Author Correction: Benralizumab Versus Placebo for Hypereosinophilic Syndrome: A Randomized, Placebo-controlled Phase 3 Trial." Nature Medicine, vol. 32, no. 6, 2026, p. 2319, https://doi.org/10.1038/s41591-026-04425-3.